| Drug Name |
Cefdinir |
| Drug ID |
BADD_D00384 |
| Description |
Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie.[A180739] Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.[A180724,A180727] |
| Indications and Usage |
Cefdinir is indicated to treat acute bacterial otitis media, acute maxillary sinusitis, community-acquired (CA) pneumonia, acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections in children and adults.[L7330,A180739]
The organisms susceptible to cefdinir have been listed below in addition to their associated clinical condition that may be treated with cefdinir.[L7330] Various beta-lactamase producing organisms may be treated, as indicated in certain sections below.
**Respiratory**
Acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis
Community-acquired pneumonia caused by Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis
**Ear, nose, and throat**
Acute bacterial otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae (penicillin-susceptible only)
Tonsillitis caused by Streptococcus pyogenes
Pharyngitis caused by Streptococcus pyogenes
Acute maxillary sinusitis caused by Haemophilus pneumoniae and Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis
**Skin and skin structure infections**
Uncomplicated skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes |
| Marketing Status |
approved |
| ATC Code |
J01DD15 |
| DrugBank ID |
DB00535
|
| KEGG ID |
D00917; D11571
|
| MeSH ID |
D000077525
|
| PubChem ID |
6915944
|
| TTD Drug ID |
D0WS1X
|
| NDC Product Code |
16714-392; 43063-959; 68071-3403; 71205-183; 71205-405; 65862-177; 16714-391; 53002-1526; 67296-1448; 68001-362; 68071-2599; 68071-5145; 68788-8404; 71205-576; 72189-185; 43063-964; 50090-6417; 68071-1645; 68180-722; 68788-7987; 68788-8115; 68788-7844; 71205-224; 72189-186; 0781-6077; 0093-4136; 0093-4137; 67296-1216; 67877-548; 16714-393; 50090-2719; 50090-3723; 65862-218; 67296-0765; 68071-2975; 68071-3156; 68788-8062; 68788-8323; 71205-380; 72189-308; 0093-3160; 50090-6171; 53002-2654; 57237-099; 63187-989; 70518-2537; 72189-423; 72789-061; 0781-6078; 68071-2493; 68071-2564; 68180-723; 68788-7339; 72189-259; 72789-054; 61788-2000; 50090-1034; 63187-616; 65862-219; 67877-543; 68071-2683; 70934-062; 72189-043; 50090-1033; 50090-5811; 50090-6042; 60687-699; 61919-840; 63187-835; 63629-8968; 67877-547; 68071-2401; 68180-711; 68788-7478; 70518-3577; 0781-2176; 65862-384; 82608-012; 50090-6041 |
| UNII |
CI0FAO63WC
|
| Synonyms |
Cefdinir | FK 482 | FK-482 | FK482 | PD 134393 | PD-134393 | 7-(2 (2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid | CI 983 | CI-983 | CI983 | Omnicef |
